With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways to treat human diseases. Anthony King reports ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...

Retinitis Pigmentosa (RP) refers to a group of inherited retinal disease, ... Vingolo EM, Mascolo S, Miccichè F, and Manco G. Retinitis pigmentosa: from pathomolecular mechanisms to therapeutic ...

Autosomal Dominant Retinitis Pigmentosa . Elucidation of the first genetic basis for ADRP came from the mapping and identification of disease-causing mutations in the rhodopsin gene. [] Since then ...

Two-year data from a phase 1/2 trial of eyeDNA Therapeutics' gene therapy for retinitis pigmentosa sets up pivotal trials, says the new biotech.

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Sidebar: Key Issues Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over ...

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...

The slackening of support from these companies coincides with the Trump administration's attacks on the LGBTQ community, ...